Merck Awarded its First CRISPR Patent by Australian Patent Office

Food and Healthcare Press Releases Thursday June 15, 2017 08:04
DARMSTADT, Germany--15 Jun--PRNewswire/InfoQuest
  • Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR
  • Similar patents pending in other countries; anticipate favorable outcomes
, a leading science and technology company, today announced that the Australian Patent Office has granted the company patent rights over the use of CRISPR in a genomic integration method for eukaryotic cells.

The patent is the first that Merck, a leader in genome editing, has received for CRISPR technology. The patent covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells ) and insertion of an external or donor DNA sequence into those cells using CRISPR.

"Merck has developed an incredible tool to give scientists the ability to find new treatments and cures for conditions for which there are limited options, including cancer, rare diseases and chronic conditions, such as diabetes," said Udit Batra, Member of the Merck Executive Board and CEO,   Life Science . "This patent decision recognizes our expertise in CRISPR technology—a body of knowledge that we are committed to grow."

Merck has patent filings for its insertion CRISPR method in Brazil, Canada, China, Europe, India, Israel, Japan, Singapore, South Korea and the U.S.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging—from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

Merck has a 14-year history in the genome-editing field. It was the first company to offer custom biomolecules for genome editing globally (TargeTron(TM) RNA-guided group II introns and CompoZr(TM) zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

With Merck's CRISPR genomic integration technology, scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creation of disease models and gene therapy.   Additionally, scientists can use the method to insert transgenes that label endogenous proteins for visual tracking within cells.

In May 2017, Merck announced that it had developed an alternative CRISPR genome-editing method called proxy-CRISPR. Unlike other systems, Merck's proxy-CRISPR technique can cut previously unreachable cell locations, making CRISPR more efficient, flexible and specific, and giving researchers more experimental options. Merck has filed several patent applications on its proxy-CRISPR technology, and those applications are just the latest of multiple CRISPR patent filings made by the company since 2012.

In addition to basic gene-editing research, Merck supports development of gene- and cell-based therapeutics and manufactures viral vectors. In 2016, Merck launched a genome-editing initiative aimed at advancing research in novel modalities—from genome editing to gene medicine manufacturing— through a dedicated team and enhanced resources, further solidifying the company's commitment to the field.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe   to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo - https://mma.prnewswire.com/media/522938/Merck_CRISPR_Patent.jpg

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics